

Lead in paragraph:

ACI is currently enrolling patients in a multicenter, randomized, placebo controlled clinical trial to evaluate the effectiveness of transdermal ondansetron for the prevention of nausea and vomiting in dogs undergoing chemotherapy with doxorubicin.

Funding:

This is a fully funded study.

Owner Participation / Commitment:

- Eligible dogs will receive doxorubicin chemotherapy and then be treated with investigational product or control product for 7 days
- Owners must monitor their dogs for the 7 days of treatment and return on days 8-10.
- Owner will be required to document study associated observations throughout the treatment period.
- In multi-animal households, the owner is able to attribute any nausea and vomiting to the dog enrolled in the study
- Dogs with frequent vomiting will be rescued with an approved anti-emetic.

Eligibility:

- Body weight: ≥ 5.0 kg
- The dog is at least 6 months of age
- Chronic conditions other than cancer should be stabilized for at least 3 months
- Dog is undergoing chemotherapy with doxorubicin at any point in their chemotherapeutic regimen

The Veterinary Investigator at the study site will determine if your pet meets other eligibility criteria and may enroll in the study.

Study Site: